STOCK TITAN
  1. Home
  2. Sec-filings
  3. GANX
  4. [424B5] Gain Therapeutics, Inc. Prospectus Supplement (Debt Securities)

[424B5] Gain Therapeutics, Inc. Prospectus Supplement (Debt Securities)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
424B5
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock GANX logo
Gain Therapeutics, Inc.

NASDAQ:GANX

GANX Rankings

#7288 Ranked by Market Cap
N/A Ranked by Dividends

GANX Latest News

Jul 16, 2025
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
Jul 15, 2025
Gain Therapeutics Announces Proposed Public Offering
Jun 30, 2025
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
Jun 10, 2025
Gain Therapeutics to Participate in Upcoming Investor Conferences
May 29, 2025
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

GANX Latest SEC Filings

Jul 17, 2025
[8-K] Gain Therapeutics, Inc. Reports Material Event
Jul 15, 2025
[424B5] Gain Therapeutics, Inc. Prospectus Supplement (Debt Securities)
Jun 30, 2025
[8-K] Gain Therapeutics, Inc. Reports Material Event
Jun 25, 2025
[Form 4] Gain Therapeutics, Inc. Insider Trading Activity
Jun 25, 2025
[Form 4] Gain Therapeutics, Inc. Insider Trading Activity

GANX Stock Data

53.00M
28.76M
5.01%
7.64%
1.32%
Biotechnology
Pharmaceutical Preparations
Link
United States
BETHESDA